Literature DB >> 14605320

Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease.

Seung-Ki Kim1, Jong-Il Yoo, Byung-Kyu Cho, Soo Jin Hong, Yong-Kook Kim, Jung-Ae Moon, Ji Ha Kim, You-Nam Chung, Kyu-Chang Wang.   

Abstract

BACKGROUND AND
PURPOSE: The etiology of moyamoya disease (MMD) remains obscure. This study was undertaken to identify specific proteins associated with the pathogenesis of MMD.
METHODS: We studied cerebrospinal fluid (CSF) from 20 patients with angiographically confirmed MMD (4 boys and 16 girls; age range, 3 to 13 years; mean, 7.5 years) and 4 control patients with cerebral palsy who underwent selective dorsal rhizotomy (2 boys and 2 girls; age range, 5 to 10 years; mean, 7.3 years). CSF proteins were analyzed by 2-dimensional polyacrylamide gel electrophoresis, and protein identification was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The presence of specific CSF protein in patients with MMD was confirmed by Western blotting. In addition, cerebral CSF was also tested in 7 patients who had other brain diseases but no MMD (2 boys and 5 girls; age range, 1 to 12 years; mean, 6.9 years).
RESULTS: We identified 1 polypeptide spot (Mr of 13 to 15 kDa and isoelectric point of 5 to 5.5) that was differentially expressed in the CSF samples of MMD patients (mean optical density intensity, 0.36+/-0.24; range, 0.05 to 0.92) and control spinal CSF samples (mean, 0.03+/-0.04; range, 0 to 0.08; P=0.002). This polypeptide was identified as cellular retinoic acid-binding protein (CRABP)-I. High levels of expression of CRABP-I in the CSF from 17 MMD children were confirmed by Western blotting.
CONCLUSIONS: The analysis of the CSF of MMD patients reveals high CRABP-I expression. The present study suggests that the elevation of CRABP-I in CSF may be a candidate for pathogenesis of MMD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605320     DOI: 10.1161/01.STR.0000100159.43123.D7

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  22 in total

Review 1.  Role of carotenoids and retinoids during heart development.

Authors:  Ioan Ovidiu Sirbu; Aimée Rodica Chiş; Alexander Radu Moise
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-01-22       Impact factor: 4.698

2.  Familial occurrence of moyamoya disease: a clinical study.

Authors:  Ho Jun Seol; Kyu-Chang Wang; Seung-Ki Kim; Yong-Seung Hwang; Ki Joong Kim; Byung-Kyu Cho
Journal:  Childs Nerv Syst       Date:  2006-03-25       Impact factor: 1.475

3.  Proteomic Analysis of Brain and Cerebrospinal Fluid from the Three Major Forms of Neuronal Ceroid Lipofuscinosis Reveals Potential Biomarkers.

Authors:  David E Sleat; Abla Tannous; Istvan Sohar; Jennifer A Wiseman; Haiyan Zheng; Meiqian Qian; Caifeng Zhao; Winnie Xin; Rosemary Barone; Katherine B Sims; Dirk F Moore; Peter Lobel
Journal:  J Proteome Res       Date:  2017-08-28       Impact factor: 4.466

4.  Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS.

Authors:  Yoshio Araki; Kazuhiro Yoshikawa; Sho Okamoto; Masaki Sumitomo; Mikio Maruwaka; Toshihiko Wakabayashi
Journal:  BMC Neurol       Date:  2010-11-08       Impact factor: 2.474

5.  Association of HLA-DR and -DQ Genes with Familial Moyamoya Disease in Koreans.

Authors:  Seok Ho Hong; Kyu-Chang Wang; Seung-Ki Kim; Byung-Kyu Cho; Myoung Hee Park
Journal:  J Korean Neurosurg Soc       Date:  2009-12-31

Review 6.  Pathological Circulating Factors in Moyamoya Disease.

Authors:  Yao-Ching Fang; Ling-Fei Wei; Chaur-Jong Hu; Yong-Kwang Tu
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

7.  Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.

Authors:  Wanyang Liu; Daisuke Morito; Seiji Takashima; Yohei Mineharu; Hatasu Kobayashi; Toshiaki Hitomi; Hirokuni Hashikata; Norio Matsuura; Satoru Yamazaki; Atsushi Toyoda; Ken-ichiro Kikuta; Yasushi Takagi; Kouji H Harada; Asao Fujiyama; Roman Herzig; Boris Krischek; Liping Zou; Jeong Eun Kim; Masafumi Kitakaze; Susumu Miyamoto; Kazuhiro Nagata; Nobuo Hashimoto; Akio Koizumi
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

Review 8.  Moyamoya Biomarkers.

Authors:  Edward R Smith
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

9.  Neuroprotective Effects of Cistanches Herba Therapy on Patients with Moderate Alzheimer's Disease.

Authors:  Nan Li; Jianping Wang; Jun Ma; Zhiqiang Gu; Chao Jiang; Lie Yu; Xiaojie Fu
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-07       Impact factor: 2.629

Review 10.  Moyamoya Disease and Spectrums of RNF213 Vasculopathy.

Authors:  Oh Young Bang; Jong-Won Chung; Dong Hee Kim; Hong-Hee Won; Je Young Yeon; Chang-Seok Ki; Hyung Jin Shin; Jong-Soo Kim; Seung Chyul Hong; Duk-Kyung Kim; Akio Koizumi
Journal:  Transl Stroke Res       Date:  2019-10-24       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.